Neoadjuvant imatinib, a treatment for gastrointestinal stromal tumors (GISTs), effectively and safely decreases tumor size, enabling less extensive surgery with a higher rate of complete resection. Among 108 GIST patients, 88% experienced reduced tumor size. Those with specific genetic mutations predicted a positive response to imatinib. Surgical complications occurred in 15% of cases, but 89% […]
Category: Sarcoma & rare tumors
Game-Changing Prognostic Models Unveiled for Gastrointestinal Melanoma
In a data-driven investigation involving 991 primary gastrointestinal melanoma patients, researchers constructed reliable prognostic models for predicting overall survival (OS) and cancer-specific survival (CSS). These models incorporated key factors like age, disease stage, lymph node density, and surgery. Rigorous testing confirmed their effectiveness, making them valuable tools for assessing the prognosis of primary gastrointestinal melanoma […]
Centralization Key for Small Intestinal Neuroendocrine Tumor Surgery: CentralChirSINET Study
Centralizing surgical care, this study investigated small intestinal neuroendocrine tumor (SI-NET) resections’ outcomes based on procedure volume. High-volume centers (HVCs) performed over five SI-NET resections annually, while low-volume centers (LVCs) did fewer. HVCs showcased better surgical quality, with more lymph nodes resected, advanced techniques, and higher success rates. Optimal SI-NET resection was prevalent in HVCs, […]